Bayer's experimental menopause drug, elinzanetant, positively reduced hot flashes and improved quality of life in Phase 3 trials, outperforming a placebo.

Bayer's experimental menopause treatment drug, elinzanetant, has shown positive results in reducing hot flashes and improving overall quality of life in Phase 3 trials. The drug, administered orally once a day, met all research goals and outperformed a placebo over a 12-week period. Insurance companies, however, may not cover the costs of new menopause drugs or require women to try other, potentially less effective, drugs before approving the newer treatments, creating challenges for women seeking access to these therapies.